Login
Pfizer NYSE: PFE
Pfizer is a research-based global biopharmaceutical company. Its global portfolio includes medicines and vaccines
| Name | Pfizer |
| Ticker | PFE |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
|
Price
52W Low/High |
42.81
33.49 / 43.45 |
| Momentum | Weak Up |
| Market cap | 239 B |
| 1Y Total Return |
19.39 %
Below Average |
| 1Y Volatility |
21.66 %
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Pfizer is a research-based global biopharmaceutical company. Its global portfolio includes medicines and vaccines
Details
| Ticker | PFE |
| Name | Pfizer |
| ISIN | US7170811035 |
| CUSIP | 717081103 |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 07/30/2021
| Close Price | 42.81 |
| 52W Low/High | 33.49 / 43.45 |
| Market cap | 239 B |
| 1Y Total Return |
19.39 %
Below Average |
| 1Y Volatility |
21.66 %
Low Risk |
| Beta | 0.45 |
| PE (trailing) |
21.73
Mid-tier |
| 12M Dividends | 3.5 |
| Last Dividend Date | 07/29/2021 |
| Dividend Yield | 8.18 % |
Fin. Strength
| Net Profit Margin | 24.9 % |
| Cash from Op. / Cur. Liabilities | 0.59 |
| Diluted Earnings / Share | 1.97 |
| ROE | 16.6 % |
| ROIC | 8.7 % |
| Price / Revenue | 5.5 |
| Price / Book | 3.5 |
| Price / CF | 15.3 |
| Current Ratio | 1.5 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | 0.58 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
44,461
|
38,137
|
41,037
|
52,673
|
52,599
|
50,992
|
|
| Gross Profit |
33,936
|
30,379
|
32,180
|
41,350
|
40,661
|
40,332
|
|
| R&D |
9,695
|
8,364
|
7,719
|
7,711
|
7,877
|
7,535
|
|
| EBITDA |
16,683
|
21,704
|
17,215
|
18,715
|
14,616
|
14,741
|
|
| Operating Income |
9,295
|
1,912
|
3,791
|
12,482
|
8,740
|
9,444
|
|
| Net Income exc. Extra |
11,091
|
15,745
|
11,476
|
21,748
|
7,298
|
7,622
|
|
| per Share | |||||||
| Diluted avg Shares |
5,662
|
5,613
|
5,750
|
6,057
|
6,092
|
6,225
|
|
| EPS exc. Extra |
1.97
|
2.80
|
1.97
|
3.60
|
1.19
|
1.22
|
|
| Dividend |
3.50
|
1.46
|
1.38
|
1.30
|
1.22
|
1.14
|
|
| Div. Yield (an.) |
9.64 %
|
4.72 %
|
3.25 %
|
3.66 %
|
3.57 %
|
3.79 %
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
158,818
|
166,336
|
155,421
|
164,612
|
168,784
|
162,929
|
|
| Cash, Eq & Invt ShortTerm |
13,667
|
10,350
|
11,619
|
11,421
|
14,560
|
19,443
|
|
| Total Current Assets |
39,533
|
34,738
|
45,290
|
34,835
|
35,878
|
41,298
|
|
| Total Non-Current Assets |
119,285
|
131,598
|
110,131
|
129,777
|
132,906
|
121,631
|
|
| Intangibles |
77,765
|
92,966
|
87,526
|
104,083
|
107,083
|
88,160
|
|
| Total Liabilities |
89,953
|
100,998
|
96,263
|
94,071
|
110,038
|
99,582
|
|
| Total Current Liabilities |
26,652
|
33,890
|
29,423
|
27,365
|
24,864
|
28,735
|
|
| Long Term Debt |
63,301
|
67,108
|
66,840
|
66,706
|
85,174
|
70,847
|
|
| Shareholder equity |
68,620
|
65,026
|
58,806
|
70,184
|
58,435
|
63,068
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
15,808
|
14,023
|
15,542
|
17,201
|
15,968
|
15,816
|
|
| Depreciation |
4,785
|
5,416
|
6,128
|
6,281
|
5,887
|
5,322
|
|
| Cash from Investing |
-5,947
|
-11,566
|
2,408
|
159
|
-7,378
|
-5,217
|
|
| Capex |
2,850
|
2,321
|
2,336
|
2,277
|
2,056
|
1,551
|
|
| Cash from Financing |
-10,256
|
-2,218
|
-18,188
|
-19,163
|
-6,964
|
-10,602
|
|
| Stock Issued |
301
|
268
|
-13,987
|
-5,142
|
-3,964
|
-4,395
|
|
| Debt (LT) Issued |
-12,798
|
5,969
|
4,381
|
-5,389
|
5,031
|
975
|
|
| Free Cash Flow |
4,688
|
22,956
|
19,583
|
30,899
|
7,345
|
18,061
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
24.9 %
|
41.3 %
|
28.0 %
|
41.3 %
|
13.9 %
|
14.9 %
|
|
| NCFO / Op.Income |
170.1 %
|
733.4 %
|
410.0 %
|
137.8 %
|
182.7 %
|
167.5 %
|
|
| Current Ratio |
1.5
|
1.0
|
1.5
|
1.3
|
1.4
|
1.4
|
|
| Financial Leverage D/E |
0.58
|
0.80
|
0.77
|
0.58
|
0.75
|
0.62
|
|
| Return on Capital Avg |
8.7 %
|
12.2 %
|
8.8 %
|
18.7 %
|
5.5 %
|
6.0 %
|
|
| Return on Shareholder Equity |
16.6 %
|
25.4 %
|
17.8 %
|
33.8 %
|
12.0 %
|
11.7 %
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available